Literature DB >> 12511760

Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial.

N B Lincoln1, T Flannaghan.   

Abstract

BACKGROUND AND
PURPOSE: There is inconclusive evidence of the effectiveness of psychological interventions for depression after stroke. We report the results from a randomized controlled trial of cognitive behavioral therapy (CBT).
METHODS: Stroke patients admitted to hospital were invited to complete mood questionnaires 1, 3 and 6 months after stroke. Patients who were depressed were invited to take part in a trial and randomly allocated to receive CBT (n=39), an attention placebo intervention (n= 43), or standard care (n=41). Outcome assessments were undertaken at 3 and 6 months after recruitment, on the Beck Depression Inventory, Wakefield Depression Inventory, Extended Activities of Daily Living scale, London Handicap Scale, and a rating of satisfaction with care.
RESULTS: There were no significant differences between the groups in patients' mood, independence in instrumental activities of daily living, handicap, or satisfaction with care.
CONCLUSIONS: CBT in the treatment of depression following stroke was found to be ineffective in this study. However, because of the small sample size, method of recruitment, and selection criteria, further randomized trials are required.

Entities:  

Mesh:

Year:  2003        PMID: 12511760     DOI: 10.1161/01.str.0000044167.44670.55

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  35 in total

1.  Models of care for late-life depression of the medically ill: examples from chronic obstructive pulmonary disease and stroke.

Authors:  Jimmy N Avari; George S Alexopoulos
Journal:  Am J Geriatr Psychiatry       Date:  2014-06-20       Impact factor: 4.105

2.  [Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity].

Authors:  H P Kapfhammer
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 3.  Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis.

Authors:  Richard M Sobel; Susan Lotkowski; Steven Mandel
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 4.  Rehabilitation treatments for adults with behavioral and psychosocial disorders following acquired brain injury: a systematic review.

Authors:  Raffaella Cattelani; Marina Zettin; Pierluigi Zoccolotti
Journal:  Neuropsychol Rev       Date:  2010-02-09       Impact factor: 7.444

5.  Non-pharmacological interventions for the improvement of post-stroke activities of daily living and disability amongst older stroke survivors: A systematic review.

Authors:  Carrie Stewart; Selvarani Subbarayan; Pamela Paton; Elliot Gemmell; Iosief Abraha; Phyo Kyaw Myint; Denis O'Mahony; Alfonso J Cruz-Jentoft; Antonio Cherubini; Roy L Soiza
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

6.  Management of depression in elderly stroke patients.

Authors:  Johan Lökk; Ahmad Delbari
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

7.  [Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness].

Authors:  W Finkenzeller; I Zobel; S Rietz; E Schramm; M Berger
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

Review 8.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Poststroke depression: a biopsychosocial approach.

Authors:  Benjamin T Mast; Sarah Vedrody
Journal:  Curr Psychiatry Rep       Date:  2006-02       Impact factor: 5.285

10.  Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.

Authors:  Robert G Robinson; Ricardo E Jorge; David J Moser; Laura Acion; Ana Solodkin; Steven L Small; Pasquale Fonzetti; Mark Hegel; Stephan Arndt
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.